VYGR

Voyager Therapeutics, Inc.

Price Chart

Latest Quote

$3.17

+0.13 (+4.28%)

Current Price

Previous Close	$3.04
Open	$2.97
Day High	$3.20
Day Low	$2.97
Volume	919,551

Fetched: 2026-07-19T08:37:05

Stock Information

Shares Outstanding	60.42M
Total Debt	$34.57M
Cash Equivalents	$141.48M
Revenue	$36.49M
Net Income	$-116.64M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$191.54M
EPS (TTM)	$-1.98
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$84.62M
Sales	$36.49M
Income	$-116.64M
Book/sh	$2.88
Cash/sh	$2.34
Employees	141

Financial Ratios

Quick Ratio	8.20
Current Ratio	8.42
Debt/Eq	19.90

Returns & Margins

ROA	-27.05%
ROE	-52.26%
Gross Margin	-243.48%
Operating Margin	-1167.37%

Ownership

Insider Ownership	15.14%
Institutional Ownership	56.28%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.03
P/S	5.25
P/B	1.10

Analyst Data

Recommendation	strong_buy
Target Price	$14.89

Technical Indicators

SMA20	$3.52
SMA50	$3.65
SMA200	$4.02
RSI	37.20
ATR	0.2050

Shares Float	44.22M
Short Float	6.95%
Short Ratio	5.93
Volatility	1.27
Rel Volume	1.13

Performance History

Week	-7.85%
Month	-10.20%
Quarter	-19.95%
6 Months	-23.24%
YTD	-21.34%
Year	-3.06%
3 Years	-67.39%
5 Years	-18.93%
10 Years	-74.72%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$3.17	924,200
2026-07-16	$3.04	683,400
2026-07-15	$3.20	627,600
2026-07-14	$3.16	904,700
2026-07-13	$3.24	1,006,100
2026-07-10	$3.44	716,500
2026-07-09	$3.68	505,300
2026-07-08	$3.73	886,800
2026-07-07	$3.78	1,651,500
2026-07-06	$3.62	556,200
2026-07-02	$3.78	1,119,200
2026-07-01	$3.60	543,000
2026-06-30	$3.50	424,900
2026-06-29	$3.58	656,700
2026-06-26	$3.59	2,305,200
2026-06-25	$3.55	499,600
2026-06-24	$3.68	639,400
2026-06-23	$3.70	481,700
2026-06-22	$3.72	575,700
2026-06-18	$3.72	664,900

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

📰 Latest News

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?

Barrons.com • 2026-07-13T06:00:00Z

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

24/7 Wall St. • 2026-07-02T13:33:43Z

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

Insider Monkey • 2026-06-30T16:34:42Z

Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation

Simply Wall St. • 2026-06-09T10:39:23Z

What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs

Insider Monkey • 2026-05-20T12:35:51Z

Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Zacks • 2026-05-07T21:55:09Z

Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut

MarketBeat • 2026-03-23T03:03:13Z

Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?

Simply Wall St. • 2026-03-12T22:06:46Z

Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates

Zacks • 2026-03-09T21:15:01Z

Voyager Therapeutics: Q4 Earnings Snapshot

Associated Press Finance • 2026-03-09T20:22:01Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$40,374,000	$80,001,000	$250,008,000	$40,907,000
Operating Revenue	$40,374,000	$80,001,000	$250,008,000	$40,907,000
Expenses
Total Expenses	$172,218,000	$163,288,000	$127,994,000	$91,744,000
Other Income Expense	$1,649,000	$622,000	$3,000	$2,653,000
Other Non Operating Income Expenses	$1,649,000	$622,000	$3,000	$2,653,000
Net Non Operating Interest Income Expense	$10,618,000	$18,328,000	$11,721,000	$1,792,000
Total Other Finance Cost	$-10,618,000	$-18,328,000	$-11,721,000	$-1,792,000
Operating Expense	$172,218,000	$163,288,000	$127,994,000	$91,744,000
General And Administrative Expense	$37,544,000	$35,920,000	$35,822,000	$30,980,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Net Interest Income	$10,618,000	$18,328,000	$11,721,000	$1,792,000
Normalized Income	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Net Income From Continuing And Discontinued Operation	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Total Operating Income As Reported	$-131,844,000	$-83,287,000	$122,014,000	$-50,837,000
Net Income Common Stockholders	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Net Income	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Net Income Including Noncontrolling Interests	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Net Income Continuous Operations	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Pretax Income	$-119,577,000	$-64,337,000	$133,738,000	$-46,392,000
Operating Income	$-131,844,000	$-83,287,000	$122,014,000	$-50,837,000
Per Share
Diluted EPS	$-2.04	$-1.13	$2.97	$-1.21
Basic EPS	$-2.04	$-1.13	$3.08	$-1.21
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-127,784,000	$-78,556,000	$126,455,000	$-44,646,000
Reconciled Depreciation	$4,060,000	$4,731,000	$4,441,000	$6,191,000
EBITDA (Bullshit earnings)	$-127,784,000	$-78,556,000	$126,455,000	$-44,646,000
EBIT	$-131,844,000	$-83,287,000	$122,014,000	$-50,837,000
Diluted Average Shares	$58,691,136	$57,667,543	$44,569,334	$38,356,810
Basic Average Shares	$58,691,136	$57,667,543	$43,020,747	$38,356,810
Diluted NI Availto Com Stockholders	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Tax Provision	$144,000	$665,000	$1,408,000	$16,000
Research And Development	$134,674,000	$127,368,000	$92,172,000	$60,764,000
Selling General And Administration	$37,544,000	$35,920,000	$35,822,000	$30,980,000
Other Gand A	$37,544,000	$35,920,000	$35,822,000	$30,980,000

Fetched: 2026-07-13

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Total Assets	$252,281,000	$393,050,000	$351,281,000	$159,356,000
Total Non Current Assets	$49,594,000	$116,241,000	$31,597,000	$34,857,000
Other Non Current Assets	$2,736,000	$2,874,000	$1,593,000	$1,515,000
Investmentin Financial Assets	$5,244,000	$65,704,000	$0	-
Current Assets	$202,687,000	$276,809,000	$319,684,000	$124,499,000
Other Current Assets	$2,277,000	$2,874,000	$2,628,000	$4,233,000
Prepaid Assets	$1,048,000	$2,760,000	$1,726,000	$779,000
Receivables	$2,915,000	$4,491,000	$84,455,000	$639,000
Accrued Interest Receivable	$1,003,000	$2,311,000	$964,000	$382,000
Accounts Receivable	$1,761,000	$1,504,000	$80,150,000	$0
Cash Cash Equivalents And Short Term Investments	$196,447,000	$266,684,000	$230,875,000	$118,848,000
Cash And Cash Equivalents	$65,300,000	$71,367,000	$68,802,000	$98,959,000
Cash Equivalents	$51,161,000	$59,658,000	$65,589,000	$91,724,000
Cash Financial	$14,139,000	$11,709,000	$3,213,000	$7,235,000
Non Current Prepaid Assets	-	-	-	-
Hedging Assets Current	-	-	-	-
Debt
Total Debt	$36,499,000	$43,726,000	$20,294,000	$23,126,000
Long Term Debt And Capital Lease Obligation	$28,659,000	$36,499,000	$17,094,000	$20,294,000
Current Debt And Capital Lease Obligation	$7,840,000	$7,227,000	$3,200,000	$2,832,000
Liabilities
Total Liabilities Net Minority Interest	$56,200,000	$93,290,000	$114,961,000	$100,336,000
Total Non Current Liabilities Net Minority Interest	$29,659,000	$43,502,000	$50,453,000	$27,745,000
Other Non Current Liabilities	$1,000,000	$1,000,000	$1,000,000	$1,001,000
Non Current Deferred Liabilities	$0	$6,003,000	$32,359,000	$6,450,000
Current Liabilities	$26,541,000	$49,788,000	$64,508,000	$72,591,000
Current Deferred Liabilities	$1,590,000	$24,394,000	$42,881,000	$59,377,000
Payables And Accrued Expenses	$8,020,000	$11,415,000	$11,813,000	$5,823,000
Payables	$5,013,000	$3,996,000	$1,604,000	$2,566,000
Accounts Payable	$5,013,000	$3,996,000	$1,604,000	$2,566,000
Equity
Common Stock Equity	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Total Equity Gross Minority Interest	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Stockholders Equity	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Gains Losses Not Affecting Retained Earnings	$32,000	$-407,000	$-48,000	$-219,000
Other Equity Adjustments	$32,000	$-407,000	$-48,000	$-219,000
Retained Earnings	$-445,905,000	$-326,184,000	$-261,182,000	$-393,512,000
Other
Ordinary Shares Number	$59,047,860	$54,731,316	$44,038,333	$38,613,891
Share Issued	$59,047,860	$54,731,316	$44,038,333	$38,613,891
Tangible Book Value	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Invested Capital	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Working Capital	$176,146,000	$227,021,000	$255,176,000	$51,908,000
Capital Lease Obligations	$36,499,000	$43,726,000	$20,294,000	$23,126,000
Total Capitalization	$196,081,000	$299,760,000	$236,320,000	$59,020,000
Additional Paid In Capital	$641,895,000	$626,296,000	$497,506,000	$452,713,000
Capital Stock	$59,000	$55,000	$44,000	$38,000
Common Stock	$59,000	$55,000	$44,000	$38,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$0	$6,003,000	$32,359,000	$6,450,000
Long Term Capital Lease Obligation	$28,659,000	$36,499,000	$17,094,000	$20,294,000
Current Deferred Revenue	$1,590,000	$24,394,000	$42,881,000	$59,377,000
Current Capital Lease Obligation	$7,840,000	$7,227,000	$3,200,000	$2,832,000
Pensionand Other Post Retirement Benefit Plans Current	$9,091,000	$6,752,000	$6,614,000	$4,559,000
Current Accrued Expenses	$3,007,000	$7,419,000	$10,209,000	$3,257,000
Investments And Advances	$5,244,000	$65,704,000	$0	-
Available For Sale Securities	$5,244,000	$65,704,000	-	-
Net PPE	$41,614,000	$47,663,000	$30,004,000	$33,342,000
Accumulated Depreciation	$-19,151,000	$-15,958,000	$-15,038,000	$-17,207,000
Gross PPE	$60,765,000	$63,621,000	$45,042,000	$50,549,000
Leases	$6,850,000	$6,487,000	$7,106,000	$12,554,000
Other Properties	$51,476,000	$54,800,000	$35,311,000	$35,662,000
Machinery Furniture Equipment	$2,439,000	$2,334,000	$2,625,000	$2,333,000
Properties	$0	$0	$0	$0
Duefrom Related Parties Current	$151,000	$676,000	$3,341,000	$257,000
Other Short Term Investments	$131,147,000	$195,317,000	$162,073,000	$19,889,000
Construction In Progress	-	-	-	-

Fetched: 2026-07-13

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-135,063,000	$-18,831,000	$74,663,000	$-15,000,000
Operating Activities
Operating Cash Flow	$-132,467,000	$-15,310,000	$77,919,000	$-12,509,000
Cash Flow From Continuing Operating Activities	$-132,467,000	$-15,310,000	$77,919,000	$-12,509,000
Operating Gains Losses	$141,000	$510,000	$178,000	$377,000
Investing Activities
Capital Expenditure	$-2,596,000	$-3,521,000	$-3,256,000	$-2,491,000
Investing Cash Flow	$125,446,000	$-94,859,000	$-141,643,000	$-7,339,000
Cash Flow From Continuing Investing Activities	$125,446,000	$-94,859,000	$-141,643,000	$-7,339,000
Financing Activities
Issuance Of Capital Stock	$0	$112,778,000	$31,121,000	$0
Financing Cash Flow	$816,000	$114,015,000	$33,645,000	$1,110,000
Cash Flow From Continuing Financing Activities	$816,000	$114,015,000	$33,645,000	$1,110,000
Net Common Stock Issuance	$0	$112,778,000	$31,121,000	$0
Common Stock Issuance	$0	$112,778,000	$31,121,000	$0
Other
End Cash Position	$68,036,000	$74,241,000	$70,395,000	$100,474,000
Beginning Cash Position	$74,241,000	$70,395,000	$100,474,000	$119,212,000
Changes In Cash	$-6,205,000	$3,846,000	$-30,079,000	$-18,738,000
Proceeds From Stock Option Exercised	$816,000	$1,237,000	$2,524,000	$1,110,000
Net Investment Purchase And Sale	$128,042,000	$-91,338,000	$-138,387,000	$-4,848,000
Sale Of Investment	$261,971,000	$374,347,000	$85,581,000	$50,000,000
Purchase Of Investment	$-133,929,000	$-465,685,000	$-223,968,000	$-54,848,000
Net PPE Purchase And Sale	$-2,596,000	$-3,521,000	$-3,256,000	$-2,491,000
Purchase Of PPE	$-2,596,000	$-3,521,000	$-3,256,000	$-2,491,000
Change In Working Capital	$-28,761,000	$34,859,000	$-66,557,000	$20,471,000
Change In Other Working Capital	$-28,807,000	$-44,842,000	$9,414,000	$23,731,000
Change In Other Current Liabilities	$-7,227,000	$-3,320,000	$-2,833,000	$-3,922,000
Change In Other Current Assets	$4,871,000	$4,597,000	$1,975,000	$3,310,000
Change In Payables And Accrued Expense	$-1,483,000	$-260,000	$8,045,000	$-1,156,000
Change In Accrued Expense	$-2,500,000	$-2,652,000	$9,007,000	$-3,148,000
Change In Payable	$1,017,000	$2,392,000	$-962,000	$1,992,000
Change In Account Payable	$1,017,000	$2,392,000	$-962,000	$1,992,000
Change In Prepaid Assets	$3,617,000	$-2,627,000	$76,000	$-1,967,000
Change In Receivables	$268,000	$81,311,000	$-83,234,000	$475,000
Changes In Account Receivables	$-257,000	$78,646,000	$-80,150,000	$0
Stock Based Compensation	$14,787,000	$14,785,000	$11,153,000	$9,344,000
Asset Impairment Charge	$0	$2,776,000	$0	$0
Amortization Of Securities	$-2,973,000	$-7,969,000	$-3,626,000	$-16,000
Depreciation Amortization Depletion	$4,060,000	$4,731,000	$4,441,000	$6,191,000
Depreciation And Amortization	$4,060,000	$4,731,000	$4,441,000	$6,191,000
Depreciation	$4,060,000	$4,731,000	$4,441,000	$6,191,000
Gain Loss On Sale Of PPE	$141,000	$510,000	$178,000	$377,000
Net Income From Continuing Operations	$-119,721,000	$-65,002,000	$132,330,000	$-46,408,000
Other Non Cash Items	-	-	-	$-2,468,000
Sale Of PPE	-	-	-	-

Fetched: 2026-07-13